Orally active PDE4 inhibitor with therapeutic potential

Area of Science:

• Medicinal Chemistry
• Pharmacology
• Drug Discovery

Background:

• Ariflo demonstrated promising results in clinical trials.
• Optimization of Ariflo's pharmacophore spatial arrangement is crucial for enhanced efficacy.
• Previous studies utilized a cyclohexane template, necessitating exploration of more diverse structures.

Purpose of the Study:

• To synthesize and evaluate novel Ariflo analogs with improved spatial arrangements of key pharmacophores.
• To investigate the biological activity and therapeutic potential of decyanated analogs and modified cyclopentyloxy moieties.
• To establish structure-activity relationships (SARs) and obtain pharmacokinetic data for lead compounds.

Main Methods:

• Synthesis of Ariflo analogs using a bicyclo[3?3?0]octane template.
• Biological evaluation of synthesized compounds for oral activity.
• Cross-species and same-species comparisons for therapeutic potential estimation.
• Structure-activity relationship (SAR) analysis and pharmacokinetic studies in rats.

Main Results:

• Several novel compounds, including 2a, 7a-b, and 12a, were synthesized and found to be orally active.
• These compounds exhibited significant therapeutic potential based on comparative evaluations.
• Structure-activity relationships were elucidated, and pharmacokinetic data for key compounds (2a, 7b) were acquired.

Conclusions:

• The bicyclo[3?3?0]octane template allows for greater stereochemical diversity, leading to potent Ariflo analogs.
• Compounds 2a, 7a-b, and 12a represent promising drug candidates with demonstrated oral bioavailability and therapeutic potential.
• Further investigation into these optimized Ariflo analogs is warranted for potential clinical application.